Latest Breaking News On - Biotechnology conference - Page 1 : comparemela.com

Primer: Packaging Plays Key Role in Nasal Delivery of Dry Powder Biologics

Considering dry powder delivery for nasally inhaled drugs? Experts say it’s key to test and evaluate primary packaging at an early stage, because selections can impact final product performance.

Aptar pharmaDrum labFibrodysplasia ossificans progressivaConsultant inhalationBiotechnology conferenceTwo industry leaders workingDry powder vaccineUnidose powder

Revolution Medicines to Participate in Upcoming Investor Conferences

01.02.2024 - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the .

Marka goldsmithHealth care conferenceRevolution medicines incGuggenheim healthcare talksBiotechnology conferenceAnnual health careRevolution medicines chartEvolution medicines kursEvolution medicines aktie

AAPS National Biotechnology Conference

AAPS National Biotechnology Conference
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesNational biotechnology conferenceBiotechnology conference

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesMartin lehrJennifer minai azaryGina cestariCompany nasdaqHc wainwright coAmerican society of clinical oncology annual meetingExchange commissionContext therapeutics incContext therapeuticsInvestigational new drug applicationRecent corporateBiotechnology conferenceImmune cell engager virtual conferenceClinical oncology annual meetingPrivate securities litigation reform act

Context Therapeutics Reports Second Quarter 2023 Operating

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June.

United statesJennifer minai azaryMartin lehrGina cestariHc wainwright coExchange commissionAmerican society of clinical oncology annual meetingContext therapeutics incCompany nasdaqInvestigational new drug applicationRecent corporateBiotechnology conferenceImmune cell engager virtual conferenceClinical oncology annual meetingPrivate securities litigation reform actMonths ended june